Takuya Komura

Takuya Komura

Auto-generated profile, based on publicly available information

Takuya Komura

Department of gastroenterology, National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
TKTakuya Komura
Takuya Komura
HTHisashi Takabatake
Hisashi Takabatake
KHKenichi Harada
Kenichi Harada
MYMasatoshi Yamato
Masatoshi Yamato
MMMasaki Miyazawa
Masaki Miyazawa
YSYoshio Sakai
Yoshio Sakai
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal malignancy known, with an extremely poor prognosis due to the lack of an efficient diagnostic scheme and no radical treatment option, except surgery. Therefore, understanding the pathophysiology of, and finding a novel biomarker to detect, PDAC should be prioritized. We observed an increase in mRNA expression of the cysteine protease inhibitor cystatin A (CSTA) in CD4+ T cells in peripheral blood cells of nine patients with PDAC, compared with the expression in seven healthy volunteers. Moreover, we confirmed significantly higher CSTA mRNA expression in a larger cohort of 41 patients with PDAC compared with that in 20 healthy volunteers. Correspondingly, the serum CSTA concentrations in 36 patients with PDAC were higher than those in 37 healthy volunteers, and this increase was correlated with PDAC clinical stage. Furthermore, the expression of CSTA and cathepsin B, which is a lysosomal cysteine protease inhibited by CSTA, was observed in tumor tissues and tumor‐infiltrating immune cells in 20 surgically resected PDAC tissues by immunohistochemical staining. Expression of CSTA was detected in some tumor tissues and many tumor‐infiltrating immune cells. Cathepsin B expression was also observed in most tumor tissues and tumor‐infiltrating immune cells. In conclusion, CSTA and its substrate cathepsin B are involved in PDAC‐related inflammation. The increment of CSTA expression in peripheral blood of patients with PDAC may have a potential role as a PDAC immunopathologic biomarker.

18 January 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
YSYoshio Sakai
Yoshio Sakai
MMMasaki Miyazawa
Masaki Miyazawa
TKTakuya Komura
Takuya Komura
TYTakeshi Yamada
Takeshi Yamada
ANAlessandro Nasti
Alessandro Nasti
SKShuichi Kaneko
Shuichi Kaneko
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy associated with an extremely poor prognosis. Chemotherapy, such as gemcitabine (GEM), is the only treatment for PDAC patients who are not suitable for radical surgical treatment; however, its anti‐tumor efficacy is limited. In this study, we investigated the host immune system response in murine PDAC models undergoing GEM treatment. We found that PDAC tumor tissues were infiltrated with a substantial number of Gr‐1+ myeloid cells and had relatively small numbers of CD4+ and CD8+ cells. In addition, there were increased numbers of myeloid cells expressing CD11b+ and Gr‐1+ in peripheral blood. When mice with PDAC tumors in the intraperitoneal cavity or liver were treated with GEM, numbers of myeloid cells in tumor tissues and in peripheral blood decreased. In contrast, numbers of CD4+ or CD8+ cells increased. In peripheral blood, the numbers of CD8+ cells expressing interferon‐gamma (IFN‐γ) were higher in GEM‐treated mice than in untreated mice. In addition, GEM treatment in combination with myeloid cell depletion further prolonged the survival of PDAC mice. The gene expression profile of peripheral blood in myeloid cell‐depleted PDAC mice treated with GEM showed biological processes related to anti‐cancer immunity, such as natural killer cell‐mediated cytotoxicity, type I IFN signaling, and co‐stimulatory signaling for T cell activation. Thus, in PDAC murine models, GEM treatment was associated with an immune response consistent with an anti‐cancer effect, and depletion of myeloid‐lineage cells played an important role in enhancing anti‐cancer immunity associated with GEM treatment.

30 August 2020 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
TKTakuya Komura
Takuya Komura
TKTakashi Kagaya
Takashi Kagaya
HTHideo Takayama
Hideo Takayama
MYMasahiro Yanagi
Masahiro Yanagi
TYTakatoshi Yoshio
Takatoshi Yoshio
MUMasashi Unoura
Masashi Unoura
Aim. Cytomegalovirus (CMV) can cause hepatitis, encephalomyelitis, and pneumonitis in immunocompromised patients. In contrast, CMV infection of immunocompetent patients can lead to the development of infectious mononucleosis and is typically self-limiting; severe complications are rare. We evaluated the pathophysiology and immunological aspects of CMV hepatitis in recently immunocompetent adult patients. Methods. We examined the clinical features and outcomes of 47 adult immunocompetent patients with CMV hepatitis (29 men, 18 women; mean age, 34±11 years) from January 2005 to August 2019 treated in our hospital. We also assayed T-cell activation to evaluate the immune responses in these patients. Results. Fever (74.5), hepatosplenomegaly (74.5), sore throat (36.2), headache (31.9), abdominal pain (27.7), lymphadenopathy (23.4), and skin rash (6.4) were present at admission. Complications included gastrointestinal injury (25.5), neuropathy (4.3), thrombocytopenia (2.1), and splenic infarction (2.1). All patients had a good clinical course without liver failure or transition to chronic liver injury. The time to recover from liver injury ranged from 12 to 142 days (mean, 43.4±28.7 days). The serum sIL-2R level, which reflects T-cell activation, was transiently elevated and correlated with the extent of hepatic inflammation. Conclusions. CMV hepatitis in immunocompetent individuals has a satisfactory outcome, but occasionally results in complications in other organs. The sIL-2R level has potential as a surrogate marker of hepatic inflammation in immunocompetent patients with CMV hepatitis.

1 January 2021 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
HTHideo Takayama
Hideo Takayama
TKTakuya Komura
Takuya Komura
TKTakashi Kagaya
Takashi Kagaya
SSSaiho Sugimoto
Saiho Sugimoto
NONoriaki Orita
Noriaki Orita
MUMasashi Unoura
Masashi Unoura
Aim. Hepatitis B virus (HBV) infection is a major public health concern worldwide. Entecavir (ETV), a first‐line nucleos(t)ide analogue (NA) for HBV, has a low risk of resistance. We evaluated the efficacy of ETV monotherapy, ratio of ETV‐resistant, and the clinical features of patients with ETV resistance. Methods. A total of 130 patients (72 males, 58 females; mean age, 61 ± 15 years) were divided into a NA‐naïve group (n = 108) and NA‐experienced group (n = 22). We examined the clinical outcomes of ETV monotherapy and associated factors. We also assessed the clinical features of 15 patients with resistance to ETV (mean, 51.0 ± 27.4 weeks). Results. Among the 130 patients, 94.1% achieved ALT normalization and 63.6% achieved serum HBV DNA negativity after ETV monotherapy for 96 weeks. Of the patients in the NA‐naïve group, 93.1% and 60.4% achieved ALT normalization and HBV DNA negativity, respectively. Of the patients in the NA‐experienced group, 100% and 74.9% achieved ALT normalization and HBV DNA negativity, respectively. Compared to patients on ETV continuously, 15 ETV‐resistant patients had a higher baseline HBV viral load. There was a significant difference in the time to HBV DNA negativity, but not ALT normalization after ETV monotherapy in these groups. Rescue treatment with other NAs led to ALT normalization in all of these patients, but not HBV DNA negativity. Conclusions. ETV monotherapy has a long‐term clinical efficacy. While some patients especially with HBV DNA high viral load developed ETV resistance, rescue treatment led to ALT normalization in these patients.

16 November 2022 in JGH Open
Verified
Journal Article
Open access
MYMasahiro Yanagi
Masahiro Yanagi
TKTakuya Komura
Takuya Komura
TKTakashi Kagaya
Takashi Kagaya
Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) is a very rare intestinal T‐cell lymphoma which is observed most frequently in the jejunum. MEITL is prone to cause intestinal perforation and the prognosis is very poor when it occurs. Here we report a fatal case of MEITL causing jejunal perforation at the time of diagnosis in a 79‐year‐old man. The patient underwent emergency surgery for jejunal perforation caused by MEITL but died 3 months after the initial visit due to prolonged peritonitis. It is desirable to establish a method to predict cases with intestinal perforation, and systematize the treatment strategies to avoid perforation.

15 October 2020 in Clinical Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TKTakuya Komura
Takuya Komura
TKTakashi Kagaya
Takashi Kagaya
NONoriaki Orita
Noriaki Orita
HTHideo Takayama
Hideo Takayama
SSSaiho Sugimoto
Saiho Sugimoto
MUMasashi Unoura
Masashi Unoura